Pharma

Your Article Summary

See Latest Articles

APP Pharmaceuticals Receives Approval for Sumatriptan Succinate Injection, USP
American Pharmaceutical Partners, 10/09/09

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced that it has received approval from the U.S. Food and Drug Administration to market Sumatriptan Succinate Injection, USP, in two dosage strengths. Sumatriptan Succinate Injection is therapeutically equivalent to the reference–listed drug Imitrex®, which is marketed by the innovator GlaxoSmithKline.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09

 See all of Drug/Product Approvals